{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:18:26Z","timestamp":1778588306250,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02397"],"award-info":[{"award-number":["2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-00356"],"award-info":[{"award-number":["2023-00356"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["-21\\u2013831381-C"],"award-info":[{"award-number":["-21\\u2013831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["#ADSF-24\\u20131284328-C"],"award-info":[{"award-number":["#ADSF-24\\u20131284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["-21\\u2013831376-C"],"award-info":[{"award-number":["-21\\u2013831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["-21\\u2013831377-C"],"award-info":[{"award-number":["-21\\u2013831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021720","name":"Olav Thon Stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008738","name":"Jeanssons Stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007436","name":"Erling-Perssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017138","name":"Region V\u00e4stra G\u00f6taland Regional Executive Board","doi-asserted-by":"publisher","award":["VGFOUREG-968476"],"award-info":[{"award-number":["VGFOUREG-968476"]}],"id":[{"id":"10.13039\/100017138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["715781"],"award-info":[{"award-number":["715781"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","award":["SS18-0040"],"award-info":[{"award-number":["SS18-0040"]}],"id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.seizure.2025.01.015","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T12:17:46Z","timestamp":1736770666000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Higher plasma total tau concentrations among patients reporting CNS-related side effects from antiseizure medication"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5907-8636","authenticated-orcid":false,"given":"Klara","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Akel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-7292","authenticated-orcid":false,"given":"Fredrik","family":"Aszt\u00e9ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-4545","authenticated-orcid":false,"given":"Johan","family":"Zelano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.seizure.2025.01.015_bib0001","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.seizure.2025.01.015_bib0002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/ane.12703","article-title":"A review of medication adherence in people with epilepsy","volume":"135","author":"Malek","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"9566","key":"10.1016\/j.seizure.2025.01.015_bib0003","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2025.01.015_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2023.10.016","article-title":"Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study","volume":"113","author":"Zelano","year":"2023","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2025.01.015_bib0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2025.01.015_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.seizure.2023.06.021","article-title":"Disparities in adherence and emergency department utilization among people with epilepsy: a machine learning approach","volume":"110","author":"Bensken","year":"2023","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2025.01.015_bib0007","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00415-022-11378-3","article-title":"Antiseizure medications (antiepileptic drugs) in adults: starting, monitoring and stopping","volume":"270","author":"Angus-Leppan","year":"2023","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2025.01.015_bib0008","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.seizure.2025.01.015_bib0009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2025.01.015_bib0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0000000000000851","article-title":"Plasma biomarkers for neurodegenerative disorders: ready for prime time?","volume":"36","author":"Balogun","year":"2023","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.015_bib0011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2025.01.015_bib0012","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00415-018-9043-0","article-title":"Significance of CSF NfL and tau in ALS","volume":"265","author":"Schreiber","year":"2018","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.015_bib0013","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2025.01.015_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23115877","article-title":"Current and future biomarkers in multiple sclerosis","volume":"23","author":"Yang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.seizure.2025.01.015_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrneurol.2013.9","article-title":"Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood","volume":"9","author":"Zetterberg","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2025.01.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20398","article-title":"Longitudinal association of total tau concentrations and physical activity with cognitive decline in a population sample","volume":"4","author":"Desai","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3596","article-title":"Examination of neurofilament light chain serum concentrations, physical activity, and cognitive decline in older adults","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.015_bib0018","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ana.25874","article-title":"Remote blood biomarkers of longitudinal cognitive outcomes in a population study","volume":"88","author":"Rajan","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2025.01.015_bib0019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eplepsyres.2017.10.003","article-title":"Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: a randomized controlled trial","volume":"138","author":"Maiti","year":"2017","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.015_bib0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S1734-1140(12)70940-4","article-title":"Level of S100B protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy","volume":"64","author":"Kacinski","year":"2012","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.seizure.2025.01.015_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17713","article-title":"Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: high plasma levels are rare but related to seizures","author":"Akel","year":"2023","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2025.01.015_bib0022","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/epi.17132","article-title":"Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus","volume":"63","author":"Giovannini","year":"2022","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.015_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.6101","article-title":"Association of nonconcussive repetitive head impacts and intense physical activity with levels of phosphorylated tau181 and total tau in plasma of young elite soccer players","volume":"6","author":"Cente","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.seizure.2025.01.015_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2023.04.020","article-title":"Progressive dysregulation of tau phosphorylation in an animal model of temporal lobe epilepsy","volume":"522","author":"Concepcion","year":"2023","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.seizure.2025.01.015_bib0025","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.015_bib0026","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.seizure.2025.01.015_bib0027","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3233\/JAD-230932","article-title":"Plasma amyloid-\u03b2, total tau, and neurofilament light chain across the Alzheimer's disease clinical spectrum: a population-based study","volume":"96","author":"Dong","year":"2023","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.seizure.2025.01.015_bib0028","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.resuscitation.2012.07.027","article-title":"Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study","volume":"84","author":"Randall","year":"2013","journal-title":"Resuscitation"},{"issue":"18","key":"10.1016\/j.seizure.2025.01.015_bib0029","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1080\/14767058.2017.1344964","article-title":"Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia","volume":"31","author":"Toorell","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.015_bib0030","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/ene.15273","article-title":"Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes","volume":"29","author":"Correia","year":"2022","journal-title":"Eur J Neurol"},{"issue":"20","key":"10.1016\/j.seizure.2025.01.015_bib0031","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1089\/neu.2019.6375","article-title":"A serum protein biomarker panel improves outcome prediction in human traumatic brain injury","volume":"36","author":"Thelin","year":"2019","journal-title":"J Neurotrauma"},{"issue":"10","key":"10.1016\/j.seizure.2025.01.015_bib0032","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1111\/epi.17713","article-title":"Neurofilament light, glial fibrillary acidic protein, and tau in a regional epilepsy cohort: high plasma levels are rare but related to seizures","volume":"64","author":"Akel","year":"2023","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2025.01.015_bib0033","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jamaneurol.2023.3530","article-title":"Tau oligomer\u2013containing synapse elimination by Microglia and astrocytes in Alzheimer disease","volume":"80","author":"Taddei","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2025.01.015_bib0034","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/neu.2019.6449","article-title":"Reduced neuron-specific enolase levels in chronic severe traumatic brain injury","volume":"37","author":"Bagnato","year":"2020","journal-title":"J Neurotrauma"},{"issue":"6","key":"10.1016\/j.seizure.2025.01.015_bib0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/jgs.15358","article-title":"Use of antiepileptic drugs and dementia risk-an analysis of finnish health register and German health insurance data","volume":"66","author":"Taipale","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"10.1016\/j.seizure.2025.01.015_bib0036","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/epi.14432","article-title":"No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: use of antiepileptic drugs and dementia risk-An analysis of Finnish health register and German health insurance data","volume":"59","author":"Helmstaedter","year":"2018","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:53:44Z","timestamp":1778586824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":36,"alternative-id":["S1059131125000214"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.015","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher plasma total tau concentrations among patients reporting CNS-related side effects from antiseizure medication","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}